University of California at Los Angeles Dept of Onc
Welcome,         Profile    Billing    Logout  
 21 Trials 
41 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Garon, Edward
HEMONC CIRM IST Lung, NCT03546361: CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

Active, not recruiting
1
24
US
Autologous Dendritic Cell-Adenovirus CCL21 Vaccine, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Jonsson Comprehensive Cancer Center, California Institute for Regenerative Medicine (CIRM), Merck Sharp & Dohme LLC, LUNGevity Foundation, National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
01/26
01/27
KEYNOTE-E46, NCT06125197: Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Recruiting
1
22
US
TILT-123, Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123), KEYTRUDA®, pembrolizumab, pembrolizumab (MK-3475)
TILT Biotherapeutics Ltd., Merck Sharp & Dohme LLC
Lung Cancer
01/26
05/26
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting
1
750
Europe, Japan, US, RoW
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
BASECAMP-1, NCT04981119: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Recruiting
N/A
200
US
Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
A2 Biotherapeutics Inc., Tempus AI
Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer
12/25
12/26
Hurvitz, Sara
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
NCT02668939: Presurgical Treatment With Single-Agent Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by Six Cycles of Docetaxel & Carboplatin With Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib in Patients With HER2/+ Operable Breast Cancer

Active, not recruiting
2
140
US
TCH, Trastuzumab, Docetaxel, carboplatin, TCTy, Lapatinib, docetaxel, TCHTy, lapatinib
Translational Oncology Research International, Sanofi, GlaxoSmithKline
Adenocarcinoma of the Breast, Tumor HER2/Neu Positive
01/16
 
NCT05113966: Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Checkmark Data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Data from P2 trial for locally advanced or metastatic TNBC
Checkmark Presentation of data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Presentation of data from P2 trial for locally advanced or metastatic TNBC
Terminated
2
30
US
Trilaciclib, G1T28, CDK 4/6 inhibitor, Sacituzumab Govitecan-hziy, Trodelvy, IMMU-132
G1 Therapeutics, Inc.
Triple Negative Breast Cancer
11/23
06/24
HER2CLIMB-04, NCT04539938: A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Active, not recruiting
2
70
US
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab deruxtecan, T-DXd, Enhertu, DS-8201
Seagen Inc.
HER2 Positive Breast Cancer
07/24
10/25
TELESCOPE, NCT06604858: Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer

Not yet recruiting
2
30
NA
Pembrolizumab, Carboplatin, Paclitaxel
MedSIR, Merk Sharp & Dohme España S.A.
Breast Cancer, Triple Negative Breast Cancer
10/26
10/26
TRIO-US B-12 TALENT, NCT04553770: Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Checkmark Presentation of data from TALENT trial for HER2 Low, HR+ breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from TALENT trial for HER2 Low, HR+ breast cancer at SABCS 2022
Recruiting
2
88
US
Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, WHO 10516
Jonsson Comprehensive Cancer Center, Translational Research in Oncology-U.S, Daiichi Sankyo Co., Ltd.
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
09/25
09/25
ZWI-ZW25-204, NCT05027139: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Active, not recruiting
1/2
52
US
Zanidatamab, ZW25, JZP598, Evorpacept, ALX148
Jazz Pharmaceuticals, ALX Oncology Inc.
HER2-expressing Cancers
04/25
09/25
NCT05511844: Study of ORM-5029 in Subjects with HER2-Expressing Advanced Solid Tumors

Active, not recruiting
1
87
US
ORM-5029
Orum Therapeutics USA, Inc.
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
04/25
10/25
Wainberg, Zev
daNIS-2, NCT04935359 / 2021-000591-10: Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) -

Completed
3
511
Europe, Canada, Japan, US, RoW
NIS793, Nab-paclitaxel, Gemcitabine, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Pancreatic Ductal Adenocarcinoma
08/24
08/24
NCT04759664: LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

Recruiting
2
117
US, RoW
LUT014 Gel (Dose 1), LUT014 Gel (Dose 2), Placebo
Lutris Pharma Ltd.
EGFRI Induced Acneiform Lesions
03/24
05/24
NCT06157892: A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Recruiting
1/2
198
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380
Seagen Inc., RemeGen Co., Ltd.
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
01/30
01/30
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
NCT05688215: Zimberelimab and Quemliclustat in Combination with Chemotherapy for the Treatment of Patients with Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Recruiting
1/2
56
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Core Biopsy, BIOPSY, CORE, CNB, Core Needle, Core Needle Biopsy, Needle Biopsy, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Quemliclustat, AB 680, AB-680, AB680, CD73 Inhibitor AB680, Zimberelimab, AB 122, AB-122, AB122, Anti-PD-1 Monoclonal Antibody GLS-010, GLS 010, GLS-010, GLS010, WBP-3055
Jonsson Comprehensive Cancer Center, Arcus Biosciences, Inc.
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
05/25
05/26
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
AMPLIFY-7P, NCT05726864: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Active, not recruiting
1/2
158
US
ELI-002 7P
Elicio Therapeutics
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
11/26
11/26
NCT03943004: Trial of DFP-14927 in Advanced Solid Tumors

Recruiting
1
30
US
DFP-14927
Delta-Fly Pharma, Inc.
Solid Tumor, Cancer
09/24
12/24
AMPLIFY-201, NCT04853017: A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Active, not recruiting
1
25
US
ELI-002 2P
Elicio Therapeutics
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
01/23
03/26
NCT04247126: A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Completed
1
105
US
SY-5609, Fulvestrant, Gemcitabine, Nab-paclitaxel
Syros Pharmaceuticals
Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
01/23
03/23
NCT05055609: Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors

Recruiting
1
85
US
TRE-515
Trethera
Solid Tumor, Adult, Oncology
12/26
06/27
NCT04237649: KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Terminated
1
77
Europe, Canada, Japan, US, RoW
KAZ954, PDR001, NIR178, NZV930
Novartis Pharmaceuticals
Solid Tumors
09/23
09/23
UCT01097-001, NCT04761601: First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

Terminated
1
32
US
UCT-01-097, Gemcitabine, Gemzar, Paclitaxel, Abraxane
1200 Pharma, LLC
Advanced Solid Tumor
02/24
02/24
NCT03970252: Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Completed
1
28
US
Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, U-101440E, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, citrovorum factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Therapeutic Conventional Surgery
Jonsson Comprehensive Cancer Center, Bristol-Myers Squibb, NovoCure Ltd.
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
05/24
05/24
NCT04294160: A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Terminated
1
122
Europe, Canada, US, RoW
Dabrafenib, DRB436, Tafinlar, LTT462, Trametinib, TMT212, Mekinist, LXH254, TNO155, Spartalizumab, PDR001, Tislelizumab, VDT482, BGBA317
Novartis Pharmaceuticals
BRAF V600 Colorectal Cancer
09/24
09/24
NCT06586515: A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting
1
530
Europe, Canada, Japan, US
LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
Eli Lilly and Company, Loxo Oncology, Inc.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
03/29
03/29
NCT05159440: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Active, not recruiting
1
70
US, RoW
TORL-2-307-MAB
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
12/24
12/25
NCT05270213: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Recruiting
1
64
US
RBS2418, Pembrolizumab
Riboscience, LLC., Oncobay Clinical, Inc
Advanced Cancer
09/25
10/25
NCT05156866: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Recruiting
1
70
US, RoW
TORL-2-307-ADC
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
01/25
01/26
NCT04857372: A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

Recruiting
1
156
Europe, Canada, Japan, US, RoW
IAG933
Novartis Pharmaceuticals
Mesothelioma
09/26
09/26
NCT05948826: First in Human Study of TORL-3-600 in Participants With Advanced Cancer

Recruiting
1
70
Canada, US
TORL-3-600
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Colorectal Cancer
09/25
09/26
NCT05462873: A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Active, not recruiting
1
30
Europe, Japan, US, RoW
QEQ278
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
02/25
02/25
NCT05838768: Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Recruiting
1
327
Europe, Japan, US, RoW
HRO761, pembrolizumab, irinotecan
Novartis Pharmaceuticals
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
05/29
05/29
KISIMA-02, NCT05846516: A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC

Recruiting
1
85
Europe, US
VSV-GP154, ATP150, ATP152, Ezabenlimab
Amal Therapeutics, Boehringer Ingelheim
Pancreatic Ductal Adenocarcinoma
12/26
03/27
Bishop, Rosa
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting
3
504
Europe, US, RoW
Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone
Acrotech Biopharma Inc.
Peripheral T Cell Lymphoma
07/30
11/30
Gutierrez, Joanna K
NCT03847519: Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Completed
1/2
24
US
ADXS-503, Lm immunotherapy, A503, Pembrolizumab, Keytruda, pembro
Advaxis, Inc.
Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
02/22
02/22
HBI-2376-101, NCT05163028: A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Recruiting
1
42
US
HBI-2376
HUYABIO International, LLC.
Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
12/24
12/24

Download Options